Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06697691

Clinical Prediction Model for In-Hospital Rebleeding in Acute Non-Variceal Upper Gastrointestinal Bleeding

ANVUGIB is a serious condition that can cause symptoms like vomiting blood or passing black stools. Although treatments have improved, about 10% to 30% of patients experience rebleeding shortly after their initial treatment, which increases the risk of death.

Currently, doctors use tools like the Glasgow-Blatchford Score, Rockall Score, and AIM65 Score to predict how patients with ANVUGIB might recover. However, these tools are not very effective at identifying patients who are at risk for rebleeding. This study aims to create a new, more accurate prediction model to help doctors identify high-risk patients earlier. The investigators believe that a new predictive model, which combines patient symptoms, lab test results, and imaging findings, will improve the ability to identify patients at high risk of rebleeding compared to existing tools.The goal is to provide doctors with a more reliable tool to guide their decisions, such as when to give preventive treatments or increase monitoring. This could lead to better outcomes and reduce the risk of complications or death.

This study uses patient data collected during routine care to develop and test the new model, ensuring the findings are directly applicable to real-world clinical settings.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

the Central Hospital of Wuhan

Wuhan, Hubei, 430000, China

Location status: Recruiting

Location contact

heng zhang

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age exceeding 18 years,
  • Clinical diagnosis of Acute Non-Variceal Upper Gastrointestinal Bleeding ,
  • patients who underwent endoscopy within 24 hours of admission with confirmation of non-variceal bleeding

Exclusion criteria

  • Upper Gastrointestinal Bleeding during hospitalization;
  • transfer from other hospitals;
  • variceal bleeding;
  • lower gastrointestinal bleeding.;
  • bleeding attributed to systemic diseases like disseminated intravascular coagulation (DIC) and hematological disorders;
  • patients with incomplete clinical data or laboratory test results;
  • patients who either requested early discharge or declined gastroscopy.

Treatment and study plan

Primary outcomes

  1. relbeeding

    Time frame: up to 7 days

    Rebleeding was defined as hematemesis, hematochezia, and/or melena within 7 days of the initial bleeding, accompanied by hemodynamic instability or a decrease in hemoglobin of at least 2 g/dl within 24 hours.

Study contacts

Contact information is provided by the study sponsor or research team.

junwei yan

CONTACT

[email protected]

+8602782211449

Sponsors and collaborators

Lead sponsor

Junwei Yan

Other

Registry information

Official study title

Construction of a Clinical Prediction Model for In-Hospital Rebleeding in Patients With Acute Non-Venous Upper Gastrointestinal Bleeding

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Nov 20, 2024
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.